This tumor specificity reduces off-target radiation exposure to healthy bone marrow, potentially lowering hematologic toxicity, and enables integration with PSMA-targeted imaging agents (e.g., 68Ga-PSMA or 89Zr-PSMA) in a theranostic framework. This evidence concerns the gene FOLH1 and neoplasm.